> Details

Pérez, Patricia; Q. Marín, María; Lázaro-Frías, Adrián; Jiménez de Oya, Nereida; Blázquez, Ana-Belén; Escribano-Romero, Estela; S. Sorzano, Carlos Óscar; Ortego, Javier; Saiz, Juan-Carlos; Esteban, Mariano; Martín-Acebes, Miguel A.; García-Arriaza, Juan

A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice
  • Contributor: Pérez, Patricia; Q. Marín, María; Lázaro-Frías, Adrián; Jiménez de Oya, Nereida; Blázquez, Ana-Belén; Escribano-Romero, Estela; S. Sorzano, Carlos Óscar; Ortego, Javier; Saiz, Juan-Carlos; Esteban, Mariano; Martín-Acebes, Miguel A.; García-Arriaza, Juan
  • Published: Springer Science and Business Media LLC, 2018
  • Published in: Scientific Reports, 8 (2018) 1
  • Language: English
  • DOI: 10.1038/s41598-018-35724-6
  • ISSN: 2045-2322
  • Origination:
  • Footnote:
  • Description: AbstractZika virus (ZIKV) is a re-emerging mosquito-borne flavivirus that affects humans and can cause severe neurological complications, including Guillain-Barré syndrome and microcephaly. Since 2007 there have been three large outbreaks; the last and larger spread in the Americas in 2015. Actually, ZIKV is circulating in the Americas, Southeast Asia, and the Pacific Islands, and represents a potential pandemic threat. Given the rapid ZIKV dissemination and the severe neurological and teratogenic sequelae associated with ZIKV infection, the development of a safe and efficacious vaccine is critical. In this study, we have developed and characterized the immunogenicity and efficacy of a novel ZIKV vaccine based on the highly attenuated poxvirus vector modified vaccinia virus Ankara (MVA) expressing the ZIKV prM and E structural genes (termed MVA-ZIKV). MVA-ZIKV expressed efficiently the ZIKV structural proteins, assembled in virus-like particles (VLPs) and was genetically stable upon nine passages in cell culture. Immunization of mice with MVA-ZIKV elicited antibodies that were able to neutralize ZIKV and induced potent and polyfunctional ZIKV-specific CD8+T cell responses that were mainly of an effector memory phenotype. Moreover, a single dose of MVA-ZIKV reduced significantly the viremia in susceptible immunocompromised mice challenged with live ZIKV. These findings support the use of MVA-ZIKV as a potential vaccine against ZIKV.
  • Access State: Open Access